Reta glucagon-like peptide-1 (GLP-1) receptor agonists provide a groundbreaking strategy to diabetes management. These innovative medications operate by mimicking the inherent actions of GLP-1, a hormone produced by the gut in response to food. By activating GLP-1 receptors in the pancreas, these substances increase insulin release and inhibit gluc

The management of diabetes is with the emergence of exciting new therapies. Among these, Reta, GLP-1 receptor agonists, Retatrutide, and Trizepatide are gaining significant traction. These medications offer promising strategies for controlling blood sugar levels and could improve the lives of individuals living with diabetes. This novel class of